Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chad E Bennett

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Organic Letters|April 26, 2003
Acid-promoted Prins cyclizations of enol ethers to form tetrahydropyransDavid J Hart, Chad E Bennett
Pharmaceutics|April 26, 2025
Translational Pharmacokinetic-Pharmacodynamic Modeling of a Novel Oral Dihydroorotate Dehydrogenase (DHODH) Inhibitor, HOSU-53 (JBZ-001)Joo Young Na, Min Hai, Kyeongmin Kim, et al.
Bioorganic & Medicinal Chemistry Letters|January 24, 2012
Fused tricyclic mGluR1 antagonists for the treatment of neuropathic painChad E Bennett, Duane A Burnett, William J Greenlee, et al.
Journal of the American Chemical Society|November 15, 2002
The practical synthesis of a novel and highly potent analogue of bryostatinPaul A Wender, Jeremy L Baryza, Chad E Bennett, et al.
Scientific Reports|November 3, 2025
OSU-ERβ-12: a promising pre-clinical candidate selective estrogen receptor beta agonistGregory M Young, Timothy H Helms, Samuel K Kulp, et al.
Bioorganic & Medicinal Chemistry Letters|August 21, 2010
Iminoheterocycles as gamma-secretase modulatorsJohn P Caldwell, Chad E Bennett, Troy M McCracken, et al.
Plos One|July 28, 2017
Target specificity, in vivo pharmacokinetics, and efficacy of the putative STAT3 inhibitor LY5 in osteosarcoma, Ewing's sarcoma, and rhabdomyosarcomaPeter Y Yu, Heather L Gardner, Ryan Roberts, et al.
Bioorganic & Medicinal Chemistry Letters|October 23, 2012
Synthesis and SAR development of novel mGluR1 antagonists for the treatment of chronic painStephanie Brumfield, Peter Korakas, Lisa S Silverman, et al.
Frontiers in Oncology|May 16, 2022
Activity of Estrogen Receptor β Agonists in Therapy-Resistant Estrogen Receptor-Positive Breast CancerJharna Datta, Natalie Willingham, Jasmine M Manouchehri, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 1, 2025
The elucidation of species-specific receptor pharmacology: A case study using subtype-selective para- and meta-carborane estrogen receptor agonistsAdeoluwa A Adeluola, Hanna S Radomska, Tyler A Wilson, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Organic Letters|April 26, 2003
Acid-promoted Prins cyclizations of enol ethers to form tetrahydropyransDavid J Hart, Chad E Bennett
Pharmaceutics|April 26, 2025
Translational Pharmacokinetic-Pharmacodynamic Modeling of a Novel Oral Dihydroorotate Dehydrogenase (DHODH) Inhibitor, HOSU-53 (JBZ-001)Joo Young Na, Min Hai, Kyeongmin Kim, et al.
Bioorganic & Medicinal Chemistry Letters|January 24, 2012
Fused tricyclic mGluR1 antagonists for the treatment of neuropathic painChad E Bennett, Duane A Burnett, William J Greenlee, et al.
Journal of the American Chemical Society|November 15, 2002
The practical synthesis of a novel and highly potent analogue of bryostatinPaul A Wender, Jeremy L Baryza, Chad E Bennett, et al.
Scientific Reports|November 3, 2025
OSU-ERβ-12: a promising pre-clinical candidate selective estrogen receptor beta agonistGregory M Young, Timothy H Helms, Samuel K Kulp, et al.
Bioorganic & Medicinal Chemistry Letters|August 21, 2010
Iminoheterocycles as gamma-secretase modulatorsJohn P Caldwell, Chad E Bennett, Troy M McCracken, et al.
Plos One|July 28, 2017
Target specificity, in vivo pharmacokinetics, and efficacy of the putative STAT3 inhibitor LY5 in osteosarcoma, Ewing's sarcoma, and rhabdomyosarcomaPeter Y Yu, Heather L Gardner, Ryan Roberts, et al.
Bioorganic & Medicinal Chemistry Letters|October 23, 2012
Synthesis and SAR development of novel mGluR1 antagonists for the treatment of chronic painStephanie Brumfield, Peter Korakas, Lisa S Silverman, et al.
Frontiers in Oncology|May 16, 2022
Activity of Estrogen Receptor β Agonists in Therapy-Resistant Estrogen Receptor-Positive Breast CancerJharna Datta, Natalie Willingham, Jasmine M Manouchehri, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 1, 2025
The elucidation of species-specific receptor pharmacology: A case study using subtype-selective para- and meta-carborane estrogen receptor agonistsAdeoluwa A Adeluola, Hanna S Radomska, Tyler A Wilson, et al.
Pageof 2